Aligning Investments in Therapeutic Development with Therapeutic Need : Closing the Gap

個数:
  • 予約

Aligning Investments in Therapeutic Development with Therapeutic Need : Closing the Gap

  • 現在予約受付中です。出版後の入荷・発送となります。
    重要:表示されている発売日は予定となり、発売が延期、中止、生産限定品で商品確保ができないなどの理由により、ご注文をお取消しさせていただく場合がございます。予めご了承ください。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Paperback:紙装版/ペーパーバック版/ページ数 244 p.
  • 言語 ENG
  • 商品コード 9780309993821
  • DDC分類 615

Full Description

The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the health of the nation and the world. The public and private sectors contribute to this advancement by funding biomedical research and development. The current level of investment in pharmaceutical development in the United States, while substantial, does not always yield desired health outcomes or meet the needs of patients. Public and private funders face a myriad of challenges that affect their funding decisions and hinder the ability of the drug development system to prioritize disease burden and unmet need - often leaving critical gaps in available treatment options.

To better understand these gaps, Gates Ventures and the Peterson Center on Healthcare asked the National Academies to examine current challenges and offer strategies and recommendations for improvement. The resulting report emphasizes that current research prioritization does not systematically account for disease burden and unmet needs, and describes how a robust, timely, accessible data system is needed. It also explores the ways in which implementing recommended policy changes could deliver better health outcomes.

Table of Contents

Front Matter
Summary
1 Introduction
2 Conceptual Foundations for Measuring Disease Burden, Unmet Need, and Investment in Therapeutic Development in the United States
3 Degree and Patterns of Mismatch Between U.S. Disease Burden and Public and Private Investment in Innovative Therapeutic Development
4 Factors Contributing to Misalignment Between Investment Priorities and Unmet Need
5 Strategies to Better Align Innovations with Disease Burden and Unmet Need
6 Recommendations
Appendix A: Public Meeting Agendas
Appendix B: Committee and Staff Biographical Sketches
Appendix C: Disclosure of Unavoidable Conflicts of Interest
Appendix D: IHME Methods

最近チェックした商品